Akero Therapeutics ((AKRO)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Akero Therapeutics is conducting a Phase 3 clinical study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH.’ The study aims to assess the safety and efficacy of Efruxifermin (EFX) in patients with liver cirrhosis caused by NASH/MASH, a significant health concern due to its potential to progress to liver failure.
The study is testing Efruxifermin, a drug administered via subcutaneous injection, against a placebo. Efruxifermin is designed to treat liver cirrhosis by targeting metabolic pathways involved in NASH/MASH.
This interventional study features a randomized, parallel assignment model with quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are all blinded to the treatment allocation. The primary purpose of the study is treatment-focused.
The study began on September 4, 2024, with the most recent update submitted on June 25, 2025. These dates are crucial as they indicate the study’s progress and the timeline for potential data availability.
The outcome of this study could significantly impact Akero Therapeutics’ stock performance and investor sentiment, as positive results may enhance the company’s market position in treating liver diseases. Competitors in the NASH/MASH treatment space will be closely monitoring these developments.
The study is currently recruiting, and further details can be accessed on the ClinicalTrials portal.